{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:02:39Z","timestamp":1772701359983,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"DOI":"10.7759\/cureus.104692","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:20:43Z","timestamp":1772698843000},"source":"Crossref","is-referenced-by-count":0,"title":["Leflunomide for Connective Tissue Diseases: A Narrative Review of Efficacy and Safety"],"prefix":"10.7759","author":[{"given":"Balakrishnan","family":"Navaneethakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahabaleshwar","family":"Mamadapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85495","article-title":"Cutaneous adverse effects of hydroxychloroquine and leflunomide in connective tissue diseases: a report of three cases and a literature review","volume":"17","author":"Bazon CA","year":"2025","unstructured":"Bazon CA, Porumb-Andrese E, Hutanu A, Orzan O, Branisteanu DE. Cutaneous adverse effects of hydroxychloroquine and leflunomide in connective tissue diseases: a report of three cases and a literature review. Cureus. 2025, 17:e85495. 10.7759\/cureus.85495","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020407","article-title":"Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review","volume":"9","author":"Vacchi C","year":"2020","unstructured":"Vacchi C, Sebastiani M, Cassone G, Cerri S, Casa GD, Salvarani C, Manfredi A. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med. 2020, 9:10.3390\/jcm9020407","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1555442","article-title":"Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review","volume":"12","author":"Xu C","year":"2025","unstructured":"Xu C, Xu Z, Ren J. Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review. Front Med (Lausanne). 2025, 12:1555442. 10.3389\/fmed.2025.1555442","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-8-7","article-title":"Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease","volume":"10","author":"Vacchi C","year":"2021","unstructured":"Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context. 2021, 10:10.7573\/dic.2020-8-7","journal-title":"Drugs Context"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002870","article-title":"Safety and efficacy of dermal fillers in patients with connective tissue disease: a review","volume":"47","author":"Gonzalez CD","year":"2021","unstructured":"Gonzalez CD, Pamatmat JJ, Goff HW. Safety and efficacy of dermal fillers in patients with connective tissue disease: a review. Dermatol Surg. 2021, 47:360-364. 10.1097\/DSS.0000000000002870","journal-title":"Dermatol Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150674","article-title":"Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"43","author":"Conway R","year":"2016","unstructured":"Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. J Rheumatol. 2016, 43:855-860. 10.3899\/jrheum.150674","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2348575","article-title":"A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis","volume":"23","author":"Sen R","year":"2024","unstructured":"Sen R, Riofrio M, Singh JA. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2024, 23:687-714. 10.1080\/14740338.2024.2348575","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061755","article-title":"Better safe than sorry: rheumatoid arthritis, interstitial lung disease, and medication \u2014 a narrative review","volume":"11","author":"Andronache IT","year":"2023","unstructured":"Andronache IT, \u015eu\u0163a VC, \u015eu\u0163a M, Ciocodei SL, Vladareanu L, Nicoara AD, Arghir OC. Better safe than sorry: rheumatoid arthritis, interstitial lung disease, and medication \u2014 a narrative review. Biomedicines. 2023, 11:1755. 10.3390\/biomedicines11061755","journal-title":"Biomedicines"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1973428","article-title":"Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases","volume":"21","author":"Vicente-Rabaneda EF","year":"2022","unstructured":"Vicente-Rabaneda EF, L\u00f3pez-Matencio JMS, Ancochea J, Blanco R, Gonz\u00e1lez-Gay M\u00c1, Casta\u00f1eda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf. 2022, 21:311-333. 10.1080\/14740338.2021.1973428","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5552","article-title":"Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders","volume":"9","author":"Said JT","year":"2021","unstructured":"Said JT, Elman SA, Merola JF. Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. Ann Transl Med. 2021, 9:430. 10.21037\/atm-20-5552","journal-title":"Ann Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01178-x","article-title":"Current and emerging drug therapies for connective tissue disease-interstitial lung disease (CTD-ILD)","volume":"79","author":"Jee AS","year":"2019","unstructured":"Jee AS, Corte TJ. Current and emerging drug therapies for connective tissue disease-interstitial lung disease (CTD-ILD). Drugs. 2019, 79:1511-1528. 10.1007\/s40265-019-01178-x","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1019915","article-title":"Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis","volume":"13","author":"Xu L","year":"2022","unstructured":"Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol. 2022, 13:1019915. 10.3389\/fphar.2022.1019915","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0314.111","article-title":"The efficacy of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis","volume":"52","author":"Zhu L","year":"2025","unstructured":"Zhu L, Mendel A, Ross C, Makhzoum JP. The efficacy of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis. J Rheumatol. 2025, 52:98. 10.3899\/jrheum.2025-0314.111","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai SC","year":"2016","unstructured":"Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016, 352:h6819. 10.1136\/bmj.h6819","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2021.03.010","article-title":"Management of connective tissue disease-associated interstitial lung disease","volume":"42","author":"Kawano-Dourado L","year":"2021","unstructured":"Kawano-Dourado L, Lee JS. Management of connective tissue disease-associated interstitial lung disease. Clin Chest Med. 2021, 42:295-310. 10.1016\/j.ccm.2021.03.010","journal-title":"Clin Chest Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45079","article-title":"Painful small fiber neuropathy associated with teriflunomide: a case series and literature review related to teriflunomide and leflunomide","volume":"15","author":"Elrefaey A","year":"2023","unstructured":"Elrefaey A, Memon AB. Painful small fiber neuropathy associated with teriflunomide: a case series and literature review related to teriflunomide and leflunomide. Cureus. 2023, 15:e45079. 10.7759\/cureus.45079","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1160755","article-title":"Immune-mediated lung diseases: a narrative review","volume":"10","author":"Sweis JJ","year":"2023","unstructured":"Sweis JJ, Sweis NW, Alnaimat F, et al.. Immune-mediated lung diseases: a narrative review. Front Med (Lausanne). 2023, 10:1160755. 10.3389\/fmed.2023.1160755","journal-title":"Front Med (Lausanne)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004044","article-title":"Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: a Case report and literature review","volume":"95","author":"Keng LT","year":"2016","unstructured":"Keng LT, Lin MW, Huang HN, Chung KP. Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: a Case report and literature review. Medicine (Baltimore). 2016, 95:e4044. 10.1097\/MD.0000000000004044","journal-title":"Medicine (Baltimore)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1470488","article-title":"Update on tocilizumab in rheumatoid arthritis: a narrative review","volume":"16","author":"Parisi S","year":"2025","unstructured":"Parisi S, Ditto MC, Ghellere F, Panaro S, Piccione F, Borrelli R, Fusaro E. Update on tocilizumab in rheumatoid arthritis: a narrative review. Front Immunol. 2025, 16:1470488. 10.3389\/fimmu.2025.1470488","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S360801","article-title":"Diagnosis and management of cutaneous manifestations of autoimmune connective tissue diseases","volume":"15","author":"Goldman N","year":"2022","unstructured":"Goldman N, Han J, LaChance A. Diagnosis and management of cutaneous manifestations of autoimmune connective tissue diseases. Clin Cosmet Investig Dermatol. 2022, 15:2285-2312. 10.2147\/CCID.S360801","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13665-022-00290-w","article-title":"Management of connective tissue disease-related interstitial lung disease","volume":"11","author":"Ahmed S","year":"2022","unstructured":"Ahmed S, Handa R. Management of connective tissue disease-related interstitial lung disease. Curr Pulmonol Rep. 2022, 11:86-98. 10.1007\/s13665-022-00290-w","journal-title":"Curr Pulmonol Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2024.106051","article-title":"A comprehensive review on the pharmacological prospects of terpinen-4-ol: from nature to medicine and beyond","volume":"176","author":"Prerna","year":"2024","unstructured":"Prerna, Chadha J, Khullar L, Mudgil U, Harjai K. A comprehensive review on the pharmacological prospects of terpinen-4-ol: from nature to medicine and beyond. Fitoterapia. 2024, 176:106051. 10.1016\/j.fitote.2024.106051","journal-title":"Fitoterapia"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.691031","article-title":"Efficacy and safety of tripterygium wilfordii Hook. F for connective tissue disease-associated interstitial lung disease:a systematic review and meta-analysis","volume":"12","author":"Li Y","year":"2021","unstructured":"Li Y, Zhu W, He H, et al.. Efficacy and safety of tripterygium wilfordii Hook. F for connective tissue disease-associated interstitial lung disease:a systematic review and meta-analysis. Front Pharmacol. 2021, 12:691031. 10.3389\/fphar.2021.691031","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103804","article-title":"Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"24","author":"Narv\u00e1ez J","year":"2025","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Roig-Kim M, Palacios-Olid J, Maym\u00f3-Paituvi P, de Daniel-Bisbe L, Lop D. Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev. 2025, 24:103804. 10.1016\/j.autrev.2025.103804","journal-title":"Autoimmun Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2016.212","article-title":"Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view","volume":"32","author":"Koo SM","year":"2017","unstructured":"Koo SM, Uh ST. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med. 2017, 32:600-610. 10.3904\/kjim.2016.212","journal-title":"Korean J Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/toxics10050274","article-title":"The anti-rheumatic drug, leflunomide, induces nephrotoxicity in mice via upregulation of TGF\u03b2-mediated p53\/Smad2\/3 signaling","volume":"10","author":"Aljohani AA","year":"2022","unstructured":"Aljohani AA, Alqarni YS, Alrashidi MN, et al.. The anti-rheumatic drug, leflunomide, induces nephrotoxicity in mice via upregulation of TGF\u03b2-mediated p53\/Smad2\/3 signaling. Toxics. 2022, 10:274. 10.3390\/toxics10050274","journal-title":"Toxics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.01.005","article-title":"Biologic therapies for autoimmune and connective tissue diseases","volume":"37","author":"Wolfe RM","year":"2017","unstructured":"Wolfe RM, Ang DC. Biologic therapies for autoimmune and connective tissue diseases. Immunol Allergy Clin North Am. 2017, 37:283-299. 10.1016\/j.iac.2017.01.005","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2047022","article-title":"Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update","volume":"18","author":"Chuprin J","year":"2022","unstructured":"Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol. 2022, 18:263-272. 10.1080\/1744666X.2022.2047022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001160","article-title":"Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice","volume":"27","author":"Yuki EF","year":"2021","unstructured":"Yuki EF, Silva CA, Aikawa NE, Romiti R, Heise CO, Bonfa E, Pasoto SG. Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol. 2021, 27:248-259. 10.1097\/RHU.0000000000001160","journal-title":"J Clin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1411190","article-title":"Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review","volume":"14","author":"Atzeni F","year":"2018","unstructured":"Atzeni F, Gerardi MC, Barilaro G, Masala IF, Benucci M, Sarzi-Puttini P. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018, 14:69-82. 10.1080\/1744666X.2018.1411190","journal-title":"Expert Rev Clin Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121209","article-title":"The effect of acknowledged and novel anti-rheumatic therapies on periodontal tissues \u2014 a narrative review","volume":"14","author":"Martu MA","year":"2021","unstructured":"Martu MA, Maftei GA, Luchian I, Stefanescu OM, Scutariu MM, Solomon SM. The effect of acknowledged and novel anti-rheumatic therapies on periodontal tissues \u2014 a narrative review. Pharmaceuticals (Basel). 2021, 14:1209. 10.3390\/ph14121209","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-024-04059-4","article-title":"Citral and triclosan synergistically silence quorum sensing and potentiate antivirulence response in Pseudomonas aeruginosa","volume":"206","author":"Chadha J","year":"2024","unstructured":"Chadha J, Ahuja P, Mudgil U, Khullar L, Harjai K. Citral and triclosan synergistically silence quorum sensing and potentiate antivirulence response in Pseudomonas aeruginosa. Arch Microbiol. 2024, 206:324. 10.1007\/s00203-024-04059-4","journal-title":"Arch Microbiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-025-00785-3","article-title":"Treatment strategies for acute exacerbation of interstitial lung disease associated with systemic autoimmune rheumatic diseases in Chinese patients: a scoping review","volume":"12","author":"Li M","year":"2025","unstructured":"Li M, Du Y, Yang X. Treatment strategies for acute exacerbation of interstitial lung disease associated with systemic autoimmune rheumatic diseases in Chinese patients: a scoping review. Rheumatol Ther. 2025, 12:815-833. 10.1007\/s40744-025-00785-3","journal-title":"Rheumatol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03148-0","article-title":"Treatment of calcinosis cutis associated with autoimmune connective tissue diseases","volume":"316","author":"Lau CB","year":"2024","unstructured":"Lau CB, Smith GP. Treatment of calcinosis cutis associated with autoimmune connective tissue diseases. Arch Dermatol Res. 2024, 316:390. 10.1007\/s00403-024-03148-0","journal-title":"Arch Dermatol Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071772","article-title":"Autoimmune connective tissue diseases-related pruritus: proper diagnosis and possible mechanisms","volume":"12","author":"Wong LS","year":"2022","unstructured":"Wong LS, Yen YT. Autoimmune connective tissue diseases-related pruritus: proper diagnosis and possible mechanisms. Diagnostics (Basel). 2022, 12:1772. 10.3390\/diagnostics12071772","journal-title":"Diagnostics (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082560","article-title":"Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis","volume":"9","author":"Erre GL","year":"2020","unstructured":"Erre GL, Sebastiani M, Fenu MA, et al.. Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. J Clin Med. 2020, 9:2560. 10.3390\/jcm9082560","journal-title":"J Clin Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cxom.2017.04.004","article-title":"Oral manifestations of autoimmune and connective tissue disorders","volume":"25","author":"Sankar V","year":"2017","unstructured":"Sankar V, Noujeim M. Oral manifestations of autoimmune and connective tissue disorders. Atlas Oral Maxillofac Surg Clin North Am. 2017, 25:113-126. 10.1016\/j.cxom.2017.04.004","journal-title":"Atlas Oral Maxillofac Surg Clin North Am"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.014","article-title":"Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation","volume":"15","author":"Levy RA","year":"2016","unstructured":"Levy RA, de Jes\u00fas GR, de Jes\u00fas NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016, 15:955-963. 10.1016\/j.autrev.2016.07.014","journal-title":"Autoimmun Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut M","year":"2018","unstructured":"Thiebaut M, Launay D, Rivi\u00e8re S, et al.. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018, 17:582-587. 10.1016\/j.autrev.2017.12.010","journal-title":"Autoimmun Rev"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816668780","article-title":"Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review","volume":"11","author":"Diamanti AP","year":"2017","unstructured":"Diamanti AP, Markovic M, Argento G, Giovagnoli S, Ricci A, Lagan\u00e0 B, D'Amelio R. Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review. Ther Adv Respir Dis. 2017, 11:64-72. 10.1177\/1753465816668780","journal-title":"Ther Adv Respir Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1504a5749","article-title":"Targeted therapies and pharmacologic advances in mucous membrane pemphigoid: a comprehensive review","volume":"15","author":"Busol VN","year":"2025","unstructured":"Busol VN, Kudryashov NV. Targeted therapies and pharmacologic advances in mucous membrane pemphigoid: a comprehensive review. Dermatol Pract Concept. 2025, 15:e20255749. 10.5826\/dpc.1504a5749","journal-title":"Dermatol Pract Concept"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20930114","article-title":"Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study","volume":"12","author":"Ying S","year":"2020","unstructured":"Ying S, Xiaomeng C, Xiaomin D, et al.. Efficacy and safety of leflunomide versus cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. Ther Adv Musculoskelet Dis. 2020, 12:10.1177\/1759720X20930114","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684699","article-title":"Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations","volume":"12","author":"Shao T","year":"2021","unstructured":"Shao T, Shi X, Yang S, et al.. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations. Front Immunol. 2021, 12:684699. 10.3389\/fimmu.2021.684699","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-024-00348-z","article-title":"Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications","volume":"44","author":"Kotani T","year":"2024","unstructured":"Kotani T, Saito T, Suzuka T, Matsuda S. Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications. Inflamm Regen. 2024, 44:35. 10.1186\/s41232-024-00348-z","journal-title":"Inflamm Regen"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/life12122101","article-title":"Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data","volume":"12","author":"Fiorentini E","year":"2022","unstructured":"Fiorentini E, Bonomi F, Peretti S, et al.. Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life (Basel). 2022, 12:2101. 10.3390\/life12122101","journal-title":"Life (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1786155","article-title":"Novel therapeutic approaches in connective tissue disease-associated interstitial lung disease","volume":"45","author":"Mulcaire-Jones E","year":"2024","unstructured":"Mulcaire-Jones E, Pugashetti JV, Oldham JM, Khanna D. Novel therapeutic approaches in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med. 2024, 45:435-448. 10.1055\/s-0044-1786155","journal-title":"Semin Respir Crit Care Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcv007","article-title":"The role of biologics in treatment of connective tissue disease-associated interstitial lung disease","volume":"108","author":"Sharp C","year":"2015","unstructured":"Sharp C, Dodds N, Mayers L, Millar AB, Gunawardena H, Adamali H. The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. QJM. 2015, 108:683-688. 10.1093\/qjmed\/hcv007","journal-title":"QJM"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04184-x","article-title":"Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Zeng L","year":"2025","unstructured":"Zeng L, Liu C, Wu Y, et al.. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025, 16:65. 10.1186\/s13287-025-04184-x","journal-title":"Stem Cell Res Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.820760","article-title":"Undifferentiated connective tissue disease in pregnancy: a topic yet to be explored","volume":"13","author":"Serena C","year":"2022","unstructured":"Serena C, Clemenza S, Simeone S, et al.. Undifferentiated connective tissue disease in pregnancy: a topic yet to be explored. Front Pharmacol. 2022, 13:820760. 10.3389\/fphar.2022.820760","journal-title":"Front Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.08.007","article-title":"Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: a systematic review","volume":"51","author":"Cota-Arce JM","year":"2021","unstructured":"Cota-Arce JM, Cota J, De Le\u00f3n-Nava MA, et al.. Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: a systematic review. Semin Arthritis Rheum. 2021, 51:1282-1290. 10.1016\/j.semarthrit.2021.08.007","journal-title":"Semin Arthritis Rheum"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100118","article-title":"An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report","volume":"3","author":"Kanani J","year":"2024","unstructured":"Kanani J, Sheikh MI. An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report. J Med Surg Public Health. 2024, 3:100118. 10.1016\/j.glmedi.2024.100118","journal-title":"J Med Surg Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461981-leflunomide-for-connective-tissue-diseases-a-narrative-review-of-efficacy-and-safety","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:20:44Z","timestamp":1772698844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461981-leflunomide-for-connective-tissue-diseases-a-narrative-review-of-efficacy-and-safety"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.104692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}